Explanipedia

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis Open

Victor Abler, Cecilia Brain, Clive Ballard, Ana Berrio, Bruce Coate , et al. · 2022

Background Pimavanserin, a selective 5-HT 2A inverse agonist/antagonist, is the only treatment approved by the US Food and Drug Administration for hallucinations and delusions associated with Parkinson's disease (PD) psychosis. Aim We aime…

The incidence of dementia‐related psychosis in people with dementia: Results from a survey of 302 U.S. healthcare providers Open

Jeanny Chen, Stephen Bell, Cecilia Brain · 2020

Background In the U.S., the incidence of dementia‐related psychosis (i.e., hallucinations and delusions) among people with dementia has been estimated at 30%. 1‐15 However, it is hypothesized that the lack of a diagnostic code and approved…

Dementia‐related psychosis in the United States: Estimated prevalence of patients treated with antipsychotics/mood stabilizers and methodology using third party claims database Open

Brett A. Ramos, Alex Whitford, Cecilia Brain · 2020

Background Dementia affects approximately 8 million people in the US and about 2.4 million experience dementia‐related psychosis, such as hallucinations and delusions 1‐15 . However, the currently treated prevalence of psychosis in dementi…

Healthcare providers’ perceptions of the efficacy of antipsychotics in dementia‐related psychosis Open

Jeanny Chen, Stephen Bell, Cecilia Brain · 2020

Background Antipsychotics are commonly used to treat dementia‐related psychosis, i.e. hallucinations and delusions in dementia due to the lack of approved pharmacological options. The treatment need is large as rates of hallucinations and …

Patient characteristics and treatment choice in a 65‐84 vs a ≥85 year old population with dementia‐related psychosis: Results from a secondary data claims study Open

Brett A. Ramos, Alex Whitford, Cecilia Brain · 2020

Background Dementia affects approximately 8 million people in the US and about 2.4 million experience dementia‐related psychosis, i.e. hallucinations and delusions, 1‐15 for which there is no approved treatment. Antipsychotics (APs) are ro…

Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists Open

Correll CU, Thomas Brevig, Cecilia Brain · 2019

Christoph U Correll,1–3 Thomas Brevig,4 Cecilia Brain4 1The Zucker Hillside Hospital, Department of Psychiatry, Glen Oaks, NY, USA; 2The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Psychiatry and Molecu…

Exploration of Treatment-Resistant Schizophrenia Subtypes Based on a Survey of 204 US Psychiatrists Open

Christoph U. Correll, Thomas Brevig, Cecilia Brain · 2019

Greater clinical burden in TRS is associated with greater illness severity and chronicity markers, suggesting a dimensional gradient from non-TRS to mild-moderate and more severe forms of TRS. Time to onset of TRS may have implications for…

Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists Open

Christoph U. Correll, Thomas Brevig, Cecilia Brain · 2019

Caregiver Burdens Associated With Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes, and Perceptions Open

Dawn I. Velligan, Cecilia Brain, Laëtitia Bouérat Duvold, Ofer Agid · 2019

Background: Previous qualitative studies indicate high caregiver burden associated with providing care for people with treatment-resistant schizophrenia (TRS). In this study, we report the first quantitative data to characterize the burden…

Identifying and characterizing treatment‐resistant schizophrenia in observational database studies Open

Linus Jönsson, Jacob Simonsen, Cecilia Brain, Steven Kymes, Louise Watson · 2019

Objectives Treatment‐resistant schizophrenia (TRS) is clinically defined as failure to respond to two antipsychotics of adequate dose and duration. An algorithm (registry TRS) was developed, for identifying patients with TRS in claim datas…

Experiences, attitudes, and perceptions of caregivers of individuals with treatment-resistant schizophrenia: a qualitative study Open

Cecilia Brain, Steven Kymes, Dana DiBenedetti, Thomas Brevig, Dawn I. Velligan · 2018

Persistent positive symptoms caused significant perceived burden, feelings of being overwhelmed and having no relief, and substantial negative impacts on caregivers' emotional and physical health. To address these substantial unmet needs, …

Stigma and Burden Among Relatives of Persons With Schizophrenia: Results From the Swedish COAST Study Open

Katarina Allerby, Birgitta Sameby, Cecilia Brain, Erik Joas, Patrick Quinlan , et al. · 2015

Stigma had an impact on quality of life at the personal and family levels, and this was associated with overall burden. Increased awareness among service providers may decrease the impact of stigma on relatives, but associations need to be…

Cognition, Adherence and Stigma in Schizophrenia. The COAST study Open

Cecilia Brain · 2015

Residual force enhancement (rFE) is observed when isometric force following an active stretch is elevated compared to an isometric contraction at corresponding muscle lengths. Acute rFE has been confirmed in vivo in upper and lower limb mu…

Cecilia Brain YOU? Author Swipe